IP Pact

Medical innovations driven by the biopharmaceutical industry have played a fundamental role in helping people live longer, healthier lives. As the global population’s health needs become increasingly complex, it is ever more essential that we research and develop life-saving medicines and vaccines to meet these challenges.

Intellectual Property (IP) has been central to great scientific advances and for ensuring that patients have access to this innovation. IP helps foster long term investment to benefit patients – today and tomorrow.

During World Intellectual Property Day on 26 April 2021 the IP Principles for Advancing Cures and Therapies (IP PACT) were launched by members of the innovative biopharmaceutical industry. The IP PACT is an unprecedented declaration affirming the industry’s strong commitment to putting patients at the heart of their approach to IP.

Speakers 

Jean-Christophe Tellier, CEO, UCB & Chair of the Biopharmaceutical CEO Roundtable (BCR)

Paola Barbarino, CEO, Alzheimer’s Disease International

Sune Stampe Sørensen, Director General, Danish Patent and Trademark Office

Thomas Cueni, Director General, IFPMA

Watch

•  Introduction to the IP Pact
• IP Pact Launch
• Camilla Sylvest, Executive Vice-President at Novo Nordisk, on the IP Pact
• CEOs and Senior Leaders of the innovative biopharmaceutical industry talk about the IP Pact